Cory Kasimov

Stock Analyst at Evercore ISI Group

(4.48)
# 254
Out of 4,757 analysts
78
Total ratings
56.36%
Success rate
20.12%
Average return

Stocks Rated by Cory Kasimov

SpringWorks Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $60$65
Current: $51.32
Upside: +26.66%
Moderna
Jan 27, 2025
Maintains: In-Line
Price Target: $60$50
Current: $34.30
Upside: +45.77%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45$50
Current: $32.23
Upside: +55.13%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45$50
Current: $28.13
Upside: +77.75%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110$125
Current: $110.83
Upside: +12.79%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115$105
Current: $71.21
Upside: +47.45%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250$1,175
Current: $698.44
Upside: +68.23%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $68.60
Upside: +23.91%
Neurocrine Biosciences
May 14, 2024
Initiates: Outperform
Price Target: $175
Current: $112.66
Upside: +55.33%
Ultragenyx Pharmaceutical
Feb 27, 2024
Maintains: Overweight
Price Target: $84$88
Current: $40.02
Upside: +119.89%
Maintains: Neutral
Price Target: $324$276
Current: $147.37
Upside: +87.28%
Initiates: Neutral
Price Target: $35
Current: $2.55
Upside: +1,272.55%
Downgrades: Neutral
Price Target: $1,520$780
Current: $4.11
Upside: +18,878.10%
Maintains: Neutral
Price Target: $225$232
Current: $317.82
Upside: -27.00%
Downgrades: Neutral
Price Target: n/a
Current: $70.09
Upside: -
Downgrades: Neutral
Price Target: n/a
Current: $116.04
Upside: -
Downgrades: Neutral
Price Target: $25$21
Current: $34.65
Upside: -39.39%
Maintains: Underweight
Price Target: $83$23
Current: $3.62
Upside: +536.24%
Maintains: Neutral
Price Target: $310$250
Current: $14.34
Upside: +1,643.38%
Maintains: Underweight
Price Target: $15$10
Current: $0.37
Upside: +2,619.61%